MOVR: Data Hub is the first and only data hub that aggregates clinical, genetic, and patient reported data for multiple nuromuscular diseases. Collection of patient data about disease progression in the era of new treatments will inform and accelerate future innovation. The combination of data collected through MOVR Data Hub will provide a comprehensive understanding of health and patient experiences in a single data repository. MOVR Data Hub has the power to transform health outcomes, accelerate drug development and drive clinical research across multiple neuromuscular diseases, helpin
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of the investigational drug, dipraglurant (ADX48621), in subjects with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID).
PADOVA: The purpose of this study is to find out what effects, good and/or bad, prasinezumab versus placebo has on Parkinson’s disease in people who are taking standard medication to manage the disease symptoms.